Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
3,703 stopped studies mapped to Carcinoma and descendants · 91% state a reason
Over the 3,703 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and… | Phase 1 / Phase 2 | terminated | Jun 26, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT03646188 | Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of… | Phase 1 | terminated | Aug 24, 2018 | SkinJect, Inc. | Application of arrays was inconsistent. | Other (stated, no rule matched) |
| NCT03575611 | Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell… | Phase 2 | suspended | Jul 2, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT00280189 | Study of Outcomes of Radiofrequency Ablation of Lung Tumors | — | suspended | Jan 20, 2006 | University of Pittsburgh | not stated | Not stated |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll… | Phase 1 / Phase 2 | terminated | May 6, 2016 | Cancer Trials Ireland | Accrual lower than anticipated and not expected to improve | Enrollment / accrual |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | N/A | withdrawn | Aug 19, 2016 | Thomas Jefferson University | Principal Investigator let the institution prior to study initiation. | Investigator |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant…(DICE) | Phase 2 | terminated | Mar 11, 2019 | Cancer Trials Ireland | Insufficient accrual | Enrollment / accrual |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or… | Phase 2 | terminated | Jun 11, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT02819752 | PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and…(PEACH) | Phase 1 | terminated | Jun 30, 2016 | Royal Marsden NHS Foundation Trust | funding pulled | Funding |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in…(TOGAR) | Phase 2 | terminated | Oct 5, 2022 | Baylor College of Medicine | Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm… | Enrollment / accrual |
| NCT06130254 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the… | Phase 1 | terminated | Nov 14, 2023 | M.D. Anderson Cancer Center | Sponsor discontinued the trial | Other (stated, no rule matched) |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | N/A | terminated | Oct 9, 2018 | OHSU Knight Cancer Institute | The study did not meet its accrual goals due to the departure of study personnel. Study team opted… | Enrollment / accrual |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Phase 1 | terminated | May 19, 2021 | Deciphera Pharmaceuticals, LLC | Trial terminated due to business decision, not based on any safety or efficacy concerns. | Safety / toxicity |
| NCT06434103 | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without… | Phase 1 / Phase 2 | withdrawn | May 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor's Strategy Adjustment | Sponsor / business decision |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced…(PIPSeN) | Phase 2 | terminated | Feb 11, 2016 | Gustave Roussy, Cancer Campus, Grand Paris | study design, change of standard of care, enrollment difficulties | Enrollment / accrual |
| NCT04908111 | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Phase 1 / Phase 2 | suspended | Jun 1, 2021 | Cancer Research UK | Sponsor has decided to permanently close recruitment | Enrollment / accrual |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | Phase 2 | withdrawn | Nov 30, 2023 | Assistance Publique - Hôpitaux de Paris | The study has been halted because the manufacturer can no longer supply the experimental treatment | Drug supply |
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor… | Phase 2 | withdrawn | Apr 6, 2026 | NGM Biopharmaceuticals, Inc | Study terminated by Sponsor | Other (stated, no rule matched) |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage… | Early Phase 1 | terminated | Nov 21, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | Phase 1 | terminated | Mar 13, 2023 | Taiho Oncology, Inc. | Sponsor's decision, not based on safety concerns | Safety / toxicity |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in… | Phase 1 / Phase 2 | terminated | Dec 29, 2023 | Therapex Co., Ltd | Sponsor's decision | Sponsor / business decision |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial…(LIDA-BII) | Phase 2 | terminated | Nov 1, 2018 | University Hospital, Montpellier | Enrollement rythm low, funding body decision. | Enrollment / accrual |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | Phase 1 | terminated | Apr 21, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT05547347 | Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With… | — | suspended | Sep 21, 2022 | Mayo Clinic | Pending biocompatibility testing | Other (stated, no rule matched) |
| NCT06110195 | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Phase 1 | terminated | Oct 31, 2023 | University of Chicago | Drug no longer being developed by manufacturer | Drug supply |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating… | Phase 4 | suspended | Feb 19, 2015 | University of Chicago | Pending data analysis | Other (stated, no rule matched) |
| NCT03386357 | Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma… | Phase 2 | terminated | Dec 29, 2017 | University of Erlangen-Nürnberg Medical School | slow recruitment | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable… | Phase 2 | terminated | Sep 8, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung… | Phase 1 | terminated | Jun 16, 2020 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT03288545 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial…(EV-103) | Phase 1 / Phase 2 | terminated | Sep 20, 2017 | Astellas Pharma Global Development, Inc. | Sponsor stopped the study after meeting enrollment targets and primary objectives, and after… | Safety / toxicity |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small… | Phase 1 | terminated | Jun 2, 2021 | The Methodist Hospital Research Institute | Poor accrual | Enrollment / accrual |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | — | withdrawn | Feb 15, 2022 | Methodist Health System | Resources | Other (stated, no rule matched) |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal… | Phase 2 | terminated | May 27, 2021 | M.D. Anderson Cancer Center | Withdrawal of funding from the supporter (Mirati Therapeutics) | Funding |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone…(CONTACT-03) | Phase 3 | terminated | Apr 8, 2020 | Hoffmann-La Roche | As the study did not meet it's primary endpoint a decision was made to terminate the study. | Other (stated, no rule matched) |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT03265496 | Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive…(CONCORDE) | N/A | terminated | Aug 29, 2017 | Centre Oscar Lambret | The number of recruted patient was not sufficient | Other (stated, no rule matched) |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic… | Phase 2 | terminated | Dec 4, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word… | N/A | terminated | May 8, 2015 | Centre Oscar Lambret | Lack of patient enrollment | Enrollment / accrual |
| NCT05742269 | Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative…(MIMIR-mTNBC) | — | terminated | Feb 23, 2023 | Karolinska University Hospital | Slow patient accrual; decreasing use of IMP. | Enrollment / accrual |
| NCT06083454 | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Oct 16, 2023 | William Zeitler | funding change | Funding |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line… | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Xencor, Inc. | Business Decision | Sponsor / business decision |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | N/A | withdrawn | Dec 16, 2025 | The Royal Wolverhampton Hospitals NHS Trust | Study no longer going ahead | Other (stated, no rule matched) |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory…(DUTHY) | Phase 2 | terminated | Nov 27, 2018 | Grupo Espanol de Tumores Neuroendocrinos | In compliance with current legislation applicable to Clinical Trials, following the instructions of… | Other (stated, no rule matched) |
| NCT04832854 | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus… | Phase 2 | terminated | Apr 6, 2021 | Hoffmann-La Roche | Study was terminated as data became available from Phase 3 trials of perioperative regimens… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 17, 2026source: clinicaltrials